GBT News and Press, Global Blood Therapeutics Inc.

Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...

The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...

Global Blood Therapeutics ( NASDAQ: GBT ) expects to consummate its $5.4B deal with Pfizer ( NYSE: PFE ) on Oct. 5, the sickle cell disease drugmaker said in a regulatory filing on Friday. Pfizer ( PFE ) in early Aug. said it had agreed to buy GBT, with an ...

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...

Summary In collaboration with stellar partners like Vertex, Crispr is aggressively expanding its robust pipeline of gene-edited medicine for various disorders. By year end, Crispr is poised to file a marketing application in Europe for exa-cel, a drug designed to treat blood disor...

Summary After a slow first half, merger and acquisition deals are heating up for the remainder of 2022. In the efforts to boost its presence in rare hematology, Pfizer recently announced it is acquiring Global Blood Therapeutics for $5.4B. Global Blood Therapeutics has several...

Summary Due to its tremendous pressure, the 2021/2022 Biotech Bear market knocked out nearly all biotech innovators. Nevertheless, certain rare companies like Regenxbio are defying bear market expectations. Asides from the recent AbbVie mega partnership, Regenxbio's RGX314 is ...

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced its support for the Sickle Cell Disease Treatment Centers Act of 2022, which was introduced today and, if passed in its current form, would authorize f...

SOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 11 th Annual Sickle Cell Disease (SCD) Therapeutics Co...